Surgery Websites
Resident Research »  Leadership »  Research Committee Members »  Kyle Cromer, PhD
Kyle Cromer, Ph.D

Kyle Cromer, Ph.D

  • Assistant Professor of Surgery
  • Division of Pediatric Surgery

Contact Information

Location Required, #001
Orchid: Orchid 0000-0002-8198-5010
Open Popup
  Dept or School    
  End Date    
  • Yale University, New Haven, CT
  • PhD
  • Genetics
  • 05/2014
  • Stanford University, Stanford, CA
  • Postdoc
  • Pediatrics
  • 06/2020
  • Harvard Medical School, Boston, MA
  • Postdoc
  • Genetics
  • 05/2016
  • Stanford University, Stanford, CA
  • Instructor
  • Pediatrics
  • 05/2022
  • While we have long known the location of disease-causing mutations in the genome, the discovery of CRISPR finally gave us the ability to correct these typos back to what they should be in healthy patients. While this effort has yielded novel therapies in the clinic, in my own lab I want to look beyond simply correcting DNA typos and instead use genome editing to introduce novel functions into cells for therapeutic purposes.
    Examples include:
    -Engineering red blood cells to deliver novel protein payloads
    -Creating genome editing strategies that bias stem cell differentiation to produce clinically relevant cell types
    -Engineering kill switches to prevent differentiation into unwanted cell types
    -Developing novel ways to regulate therapeutic protein stability and expression using small molecules
    -Multiplexing editing in order to introduce multiple genome editing events simultaneously (such as correcting a disease-causing mutation and adding a kill switch that could be activated in the case of an adverse event)

    With special focus on hematopoietic stem cells and red blood cells, my main goal is to close the gap between synthetic biologists and clinicians in order to address current bottlenecks in treating the hemoglobinopathies and other blood disorders. While this is my current focus, the tools I am developing are cell type- and disease-agnostic and I am always open to expanding these concepts into new areas.
      Confired By    
  • New Frontier Research Award
  • UCSF Program for Breakthrough Biomedical Research
  • 2023 - 2024
  • Chancellor's Award
  • UCSF Academic Senate
  • 2023 - 2023
  • Junior Faculty Scholar Award
  • American Society of Hematology
  • 2023 - 2024
  • Career Development Award
  • American Society of Gene & Cell Therapy
  • 2022 - 2022
  • Honorary Mention
  • Prix Ars Electronica
  • 2021 - 2021
  • Star Mentor Award
  • Stanford Bio-X
  • 2021 - 2021
  • Conference Travel Fellowship
  • Yale Graduate Student Assembly
  • 2012 - 2012
  • Data provided by UCSF Profiles, powered by CTSI
    ORCID iD: 0000-0002-8198-5010 Additional info
    • Developing gene therapy strategies to correct a-thalassemia
      Sponsor ID:
      Funding Period:
      Jan 2022
      Dec 2025
    • Developing a CRISPR/AAV-mediated genome editing strategy to correct a-thalassemia
      Sponsor ID:
      Funding Period:
      Jan 2022
      Dec 2022
      Principal Investigator
    Data provided by UCSF Profiles, powered by CTSI
    1. Cromer MK, Majeti KR, Rettig GR, Murugan K, Kurgan GL, Bode NM, Hampton JP, Vakulskas CA, Behlke MA, Porteus MH. Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells. Mol Ther. 2023 04 05; 31(4):1074-1087. View in PubMed
    2. Cromer MK, Barsan VV, Jaeger E, Wang M, Hampton JP, Chen F, Kennedy D, Xiao J, Khrebtukova I, Granat A, Truong T, Porteus MH. Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells. Nat Commun. 2022 08 11; 13(1):4724. View in PubMed
    3. Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, Frock RL, Kenrick J, Lee C, Talbott N, Skowronski J, Cromer MK, Charlesworth CT, Bak RO, Mantri S, Bao G, DiGiusto D, Tisdale J, Wright JF, Bhatia N, Roncarolo MG, Dever DP, Porteus MH. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021 06 16; 13(598). View in PubMed
    4. Cromer MK, Camarena J, Martin RM, Lesch BJ, Vakulskas CA, Bode NM, Kurgan G, Collingwood MA, Rettig GR, Behlke MA, Lemgart VT, Zhang Y, Goyal A, Zhao F, Ponce E, Srifa W, Bak RO, Uchida N, Majeti R, Sheehan VA, Tisdale JF, Dever DP, Porteus MH. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells. Nat Med. 2021 04; 27(4):677-687. View in PubMed
    5. de Alencastro G, Puzzo F, Pavel-Dinu M, Zhang F, Pillay S, Majzoub K, Tiffany M, Jang H, Sheikali A, Cromer MK, Meetei R, Carette JE, Porteus MH, Pekrun K, Kay MA. Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex. Mol Ther. 2021 03 03; 29(3):1016-1027. View in PubMed
    6. View All Publications


    Site Directory